A Phase II Study of 13-cis Retinoic Acid Plus Interferon α-2a in Advanced Stage Penile Carcinoma: An Eastern Cooperative Oncology Group Study (E3893)

Purpose. Combined biological therapy with 13-cis-retinoic acid (13-cRA) and interferon alpha-2a (IFN α-2a) was reported to be highly effective in squamous cell carcinoma of the cervix and skin. Squamous cell carcinoma of the penis is rare in the United States, accounting for less than1 2% of all mal...

Full description

Saved in:
Bibliographic Details
Published in:Cancer investigation 2003, Vol.21 (1), p.41-46
Main Authors: Skeel, Roland T., Huang, Jie, Manola, Judith, Wilding, George, Dreicer, Robert, Walker, Paul, Muggia, Franco, Crawford, E. David, Dutcher, Janice P., Loehrer, Patrick J.
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
Medical sciences
Pharmacology. Drug treatments
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose. Combined biological therapy with 13-cis-retinoic acid (13-cRA) and interferon alpha-2a (IFN α-2a) was reported to be highly effective in squamous cell carcinoma of the cervix and skin. Squamous cell carcinoma of the penis is rare in the United States, accounting for less than1 2% of all male malignancies. Because of the association of infection with human papillomavirus with both carcinomas of the cervix and penis and their shared squamous cell histology, we carried out a phase II study of 13-cRA and IFN α-2a in carcinoma of the penis. Materials and Methods. Eighteen ambulatory patients with surgically unresectable, recurrent, and or metastatic squamous cell carcinoma of the penis were treated with IFN α-2a, 3 MU day administered subcutaneously and 13-cRA, l mg kg orally daily for at least eight weeks, unless intolerable toxicity occurred. Results. One patient was ineligible; one patient withdrew prior to treatment. Among the 16 eligible, treated patients, there was one complete response. Fourteen patients had progressive disease as their only treatment effect. Two patients were unevaluable for tumor response because they had no follow-up tumor measurements. No unexpected treatment-related toxicities were found on study. The only common form of grade 3 toxicity was hypertriglyceridemia found in eight of the 17 patients (47%). No toxicities above grade 3 were observed. Conclusion. In contrast to its benefit in squamous cell carcinomas of the cervix and skin, the combination of 13-cRA and IFN α-2a has low efficacy in advanced carcinoma of the penis.
ISSN:0735-7907
1532-4192
DOI:10.1081/CNV-120016402